<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669757</url>
  </required_header>
  <id_info>
    <org_study_id>LP0155-1375</org_study_id>
    <secondary_id>2018-000140-26</secondary_id>
    <nct_id>NCT03669757</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis</brief_title>
  <official_title>A Phase 1b, Randomised, Controlled, Observer-blinded Trial to Assess Safety, Tolerability and Pharmacodynamic Effects of LEO 134310 Cutaneous Solution in Descaled Skin of Adults With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Actual">February 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intra-individual comparison of all treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The trial will be performed investigator-blind with random assignment of the 4 Investigational Medicinal Products (IMPs), the placebo and the active comparator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall number of treatment-emergent adverse events.</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent application site reactions, by treatment.</measure>
    <time_frame>Up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Day 4, Day 8 and Day 12 in haematology parameters</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>red blood cells, white blood cells, hemoglobin, hematocrit, MCH, MMCV, MCHC, platelets, white cell differentials, measure in SI units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Day 4, Day 8 and Day 12 in clinical chemistry parameters</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>sodium, potassium, chloride, bicarbonate, blood urea nitrogen, glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaGT, uric acid, calcium, phosphate, albumin, triglycerides, cholesterol, lactate dehydrogenase, total protein, creatinine, total bilirubin, direct bilirubin, indirect bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Day 4, Day 8 and Day 12 in urinalysis parameters</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Single parameters only to be listed if deviation from usual urine dip test, e.g., sediment, leucocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal clinical significant ECG evaluation</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Evaluation of 12-lead ECG (overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant')</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal clinically significant findings of physical examination at Day 12.</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Evaluation of physical examination (areas skin, heart, lung, abdomen, basic neurological status, general examination of eyes, ears, nose throat), overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Day 4, Day 8, Day 12 in systolic and diastolic blood pressure.</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Day 4, Day 8 and Day 12 in pulse.</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>measured in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Day 4, Day 8 and Day 12 in oral body temperature.</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>measured in degrees celsius</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 4, Day 8 and Day 12 in psoriatic infiltrate thickness (assessed by measurement of the thickness of the Echo Poor Band [EPB] of the inflammatory infiltrate using 22-MHz sonography)</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 12 in disease severity</measure>
    <time_frame>12 days</time_frame>
    <description>Clinical assessment of change in disease severity (a global assessment performed by an investigator using a 5-point score ('-1 = worsened', '0 = unchanged', '1 = slight improvement', '2 = clear improvement but not completely healed', '3 = completely healed')</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 134310 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 134310 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 134310 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 134310 Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 134310 vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% betamethasone valerate ointment (class III steroid)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 134310</intervention_name>
    <description>Active substance: LEO 134310 is a compound in development at LEO Pharma A/S</description>
    <arm_group_label>LEO 134310 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 134310</intervention_name>
    <description>Active substance: LEO 134310 is a compound in development at LEO Pharma A/S</description>
    <arm_group_label>LEO 134310 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 134310</intervention_name>
    <description>Active substance: LEO 134310 is a compound in development at LEO Pharma A/S</description>
    <arm_group_label>LEO 134310 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 134310</intervention_name>
    <description>Active substance: LEO 134310 is a compound in development at LEO Pharma A/S</description>
    <arm_group_label>LEO 134310 Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 134310 vehicle</intervention_name>
    <description>Active substance: none</description>
    <arm_group_label>LEO 134310 vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% betamethasone valerate ointment (class III steroid)</intervention_name>
    <description>Active substance: betamethasone valerate</description>
    <arm_group_label>0.1% betamethasone valerate ointment (class III steroid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18-64 years (inclusive) with plaque psoriasis in a chronic stable phase.

          -  Men or women of non-child bearing potential.

        Exclusion Criteria:

          -  Acute psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, pustular,
             exfoliative or inverse psoriasis.

          -  According to defined washout periods: topical antipsoriatic drugs (except salicylic
             acid in petroleum jelly); systemic antipsoriatics and biologics; ultraviolet (UV)
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

